Medical cannabis (or medical marijuana) refers to the use of cannabis and its constituent cannabinoids, to treat disease or improve symptoms. Cannabis is used to reduce nausea and vomiting during chemotherapy, to improve appetite in people with HIV/AIDS, and to treat chronic pain and muscle spasms. Cannabinoids are under preliminary research for their potential to affect stroke.
I’m an MS Warrior and I use and LOVE the pain relief rub as well as the Cinnamon CBD oil. My Dad has told me he feels 20 again. I’m sticking with what works for us and that’s HempWorx! I don’t love it because I sell it, I sell it because I love it. I started as a customer and moved to the other side because I work from home and why not since I use the stuff anyways! CannaBossBabe and not ashamed of that. 🙂
The objectivity of scientific evaluation of the medicinal value of marijuana to date has been questioned. In the words of Hirst et al. (1998): “The ...status of cannabis has made modern clinical research almost impossible. This is primarily because of the legal, ethical and bureaucratic difficulties in conducting trials with patients. Additionally, the general attitude towards cannabis, in which it is seen only as a drug of abuse and addiction, has not helped.” In a recent editorial, the respected journal Nature (2001) stated: “Governments, including the US federal government, have until recently refused to sanction the medical use of marijuana, and have also done what they can to prevent its clinical testing. They have defended their inaction by claiming that either step would signal to the public a softening of the so-called ‘war on drugs.’... The pharmacology of cannabinoids is a valid field of scientific investigation. Pharmacologists have the tools and the methodologies to realize its considerable potential, provided the political climate permits them to do so.” Given these current demands for research on medicinal marijuana, it will be necessary to produce crops of drug types of C. sativa.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
CBD is a compound called a cannabinoid, says Jordan Tishler, MD, a Harvard-trained doc who is an expert on using cannabis as medical treatment. It can be extracted from hemp or marijuana, two different plants from the Cannabis sativa L. ("cannabis") species. The big difference between the two: Marijuana contains higher levels of tetrahydrocannabinol ("THC"), the compound responsible for the psychoactive properties of pot (a.k.a., the stuff that makes you high). Hemp, on the other hand, is naturally very low in THC (0.3 percent), says Tishler.
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
The genus Cannabis was formerly placed in the nettle (Urticaceae) or mulberry (Moraceae) family, and later, along with the genus Humulus (hops), in a separate family, the hemp family (Cannabaceae sensu stricto). Recent phylogenetic studies based on cpDNA restriction site analysis and gene sequencing strongly suggest that the Cannabaceae sensu stricto arose from within the former family Celtidaceae, and that the two families should be merged to form a single monophyletic family, the Cannabaceae sensu lato.
^ Jump up to: a b Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S, Torrens M, Pujol J, Farré M, Martin-Santos R (2013). "Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings". PLOS One. 8 (2): e55821. Bibcode:2013PLoSO...855821B. doi:10.1371/journal.pone.0055821. PMC 3563634. PMID 23390554. The most consistently reported brain alteration was reduced hippocampal volume which was shown to persist even after several months of abstinence in one study and also to be related to the amount of cannabis use Other frequently reported morphological brain alterations related to chronic cannabis use were reported in the amygdala the cerebellum and the frontal cortex...These findings may be interpreted as reflecting neuroadaptation, perhaps indicating the recruitment of additional regions as a compensatory mechanism to maintain normal cognitive performance in response to chronic cannabis exposure, particularly within the prefrontal cortex area.
In 1976, Canadian botanist Ernest Small and American taxonomist Arthur Cronquist published a taxonomic revision that recognizes a single species of Cannabis with two subspecies: C. sativa L. subsp. sativa, and C. sativa L. subsp. indica (Lam.) Small & Cronq. The authors hypothesized that the two subspecies diverged primarily as a result of human selection; C. sativa subsp. sativa was presumably selected for traits that enhance fiber or seed production, whereas C. sativa subsp. indica was primarily selected for drug production. Within these two subspecies, Small and Cronquist described C. sativa L. subsp. sativa var. spontanea Vav. as a wild or escaped variety of low-intoxicant Cannabis, and C. sativa subsp. indica var. kafiristanica (Vav.) Small & Cronq. as a wild or escaped variety of the high-intoxicant type. This classification was based on several factors including interfertility, chromosome uniformity, chemotype, and numerical analysis of phenotypic characters.
^ Advocates of legalizing marijuana for recreational use, such as Illinois state Senator Heather Steans, has said that legalizing it would help reduce such hazardous added drugs: "Over 95 percent are buying it on the black market. You don’t know what you’re buying. It’s not a safe product. We’ve seen it laced with rat poison, fentanyl, all sorts of things. It’s funding the cartels and other criminal activity."
Cannabis plants can be male, female, or hermaphrodite. The dried marijuana flowers that humans consume, however, come from the female plant. That’s because female plants produce large resin-secreting flowers that are rich in cannabinoids and free of seeds. Hence, female plants are the ones growers prefer, though of course, male marijuana plants are a requirement for pollination.
Fig. 8. Scanning electron micrographs of the abaxial surface of a perigonal bract (which envelops the fruit). These bracts are the most intoxicating part of the plant, and may contain 20% THC, dry weight. The resin is synthesized both in stalked and sessile glands. Multicellular secretory glands (of phallic appearance), some broken stalks of these (note cellular appearance), and unicellular cystolith hairs (claw-like structures) are pictured. Fig. 9. Some important cannabinoids of cannabis resin. D9-THC (delta-9 tetrahydrocannabinol) is the chief intoxicant chemical and predominates in intoxicant strains, while the isomer D8-THC is usually present in no more than trace amounts. CBD (cannabidiol) is the chief non-intoxicant chemical, and predominates in non-intoxicant strains; it has sedative effects. The non-intoxicant CBN (cannabinol) is a frequent degradation or oxidation product. The non-intoxicant cannabichromene (CBC) is typically found in trace amounts in intoxicant strains. The non-intoxicant cannabigerol (CBG) is considered to be a precursor of the other cannbinoids (see Fig. 10).
It seems like everyone and her sister (and grandma, and aunt and second cousin twice-removed, and ... you get it) is sprinkling CBD oil in her smoothies because of claims it can help with everything from pain to anxiety. But what about CBD's sister: hemp oil? Are hemp oil benefits legit? Proponents say it can help with sleep and anxiety, balance your hormones, make your skin glow, and protect your ticker. But here's what you should know before you start drizzling it on top of your food or slathering it on your skin.
The scientific debate regarding taxonomy has had little effect on the terminology in widespread use among cultivators and users of drug-type Cannabis. Cannabis aficionados recognize three distinct types based on such factors as morphology, native range, aroma, and subjective psychoactive characteristics. Sativa is the most widespread variety, which is usually tall, laxly branched, and found in warm lowland regions. Indica designates shorter, bushier plants adapted to cooler climates and highland environments. Ruderalis is the informal name for the short plants that grow wild in Europe and Central Asia.
Will hemp commercial cultivation resume in the US in the foreseeable future? This is difficult to judge, but the following considerations suggest this might occur: (1) increasing awareness of the differences between industrial hemp and marijuana; (2) growing appreciation of the environmental benefits of hemp cultivation; (3) continuing demonstration of successful hemp cultivation and development in most of the remaining western world; all the G8 countries, except the US, produce and export industrial hemp; and (4) increasing pressure on state and federal governments to permit hemp cultivation by farmers, particularly wheat, corn, and tobacco farmers in desperate need of substitute crops, but also for rotation crops to break pest and disease cycles.
Cannabidiol has been found to act as an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It has also been found to act as an inverse agonist of GPR3, GPR6, and GPR12. Although currently classified as orphan receptors, these receptors are most closely related phylogenetically to the cannabinoid receptors. In addition to orphan receptors, CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist, and this action may be involved in its antidepressant, anxiolytic, and neuroprotective effects. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD have additionally been attributed to PPARγ agonism and intracellular calcium release.
What makes CBD so appealing is that it’s non-intoxicating, so it won’t get you high, though it “is technically psychoactive, because it can influence things like anxiety,” Jikomes said. Although much of the marketing blitz around CBD centers on the fact that you can take it without getting stoned, there isn’t much research looking at the effects of CBD when used in isolation, with a couple of exceptions. One is the use of CBD to treat seizures: CBD is the active ingredient in the only cannabis product that the Food and Drug Administration has signed off on — a drug called Epidiolex, which is approved for treating two rare forms of epilepsy. Animal models and a few human studies suggest that CBD can help with anxiety, but those are the only conditions with much research on CBD in isolation.
Cannabis drug preparations have been employed medicinally in folk medicine since antiquity, and were extensively used in western medicine between the middle of the 19th century and World War II, particularly as a substitute for opiates (Mikuriya 1969). A bottle of commercial medicinal extract is shown in Fig. 41. Medical use declined with the introduction of synthetic analgesics and sedatives, and there is very limited authorized medical use today, but considerable unauthorized use, including so-called “compassion clubs” dispensing marijuana to gravely ill people, which has led to a momentous societal and scientific debate regarding the wisdom of employing cannabis drugs medically, given the illicit status. There is anecdotal evidence that cannabis drugs are useful for: alleviating nausea, vomiting, and anorexia following radiation therapy and chemotherapy; as an appetite stimulant for AIDS patients; for relieving the tremors of multiple sclerosis and epilepsy; and for pain relief, glaucoma, asthma, and other ailments [see Mechoulam and Hanus (1997) for an authoritative medical review, and Pate (1995) for a guide to the medical literature]. To date, governmental authorities in the US, on the advice of medical experts, have consistently rejected the authorization of medical use of marijuana except in a handful of cases. However, in the UK medicinal marijuana is presently being produced sufficient to supply thousands of patients, and Canada recently authorized the cultivation of medicinal marijuana for compassionate dispensation, as well as for a renewed effort at medical evaluation.
Living a healthy life means making lifestyle choices that support your physical, mental, spiritual, and emotional well-being. Managing your health can be challenging at times; while one facet of your wellness demands more attention than others, you may end up struggling to maintain a good balance in other areas. To be of sound body, mind, and spirit, it’s important to pay attention to all aspects of health—your mental, emotional, and spiritual sides all play a role in your physical welfare, and vice versa. A state of optimal well-being means more than just the absence of disease or disorder; it also means having the resources to cope with problems and circumstances beyond your control and recover from difficult or troubling situations. This intersection between health and behavior can help you prevent or at least delay chronic illness, and steer you to make better decisions about your well-being.
"Skunk" refers to several named strains of potent cannabis, grown through selective breeding and sometimes hydroponics. It is a cross-breed of Cannabis sativa and C. indica (although other strains of this mix exist in abundance). Skunk cannabis potency ranges usually from 6% to 15% and rarely as high as 20%. The average THC level in coffee shops in the Netherlands is about 18–19%.
Luke Zigovits, chief executive of Wisconsin-based Hemp Science, said, “We can finally relax. Because now we can source seed, now we can sell our product across state lines. Prohibition is over. It broadens horizons, allowing universities to do research, for example.” Beyond moving the industry into legitimacy, Zigovits said there are opportunities for tobacco farmers in Wisconsin and elsewhere to start growing industrial hemp crops as well.
More recent studies have focused on the mechanisms behind the schizophrenia–cannabis interaction. Epstein and Kumra (2014) tested the effect of cannabis on executive control of attention and cognitive function by comparing scores on the Attention Network Test among people with early-onset schizophrenia (EOS) and cannabis use disorder, only EOS, only cannabis use disorder, and controls. They found that the first group in particular had less efficient executive control of attention compared with those who had only EOS. They also found a smaller right caudal anterior cingulate cortex in subjects with EOS and cannabis use disorder. However, it is presently unclear whether this means that the smaller cortex surface leads to deficits in self-regulation and heavy cannabis use or if the direction of causation is in the opposite direction. More recent studies have suggested gene–environment correlation between cannabis use and schizophrenia in that the increased risk of schizophrenia after heavy and consistent cannabis use may be moderated by a shared gene that may explain part of the association (Power et al., 2014).
But be wary of the products you buy and do your research. Some cannabis products work while many don’t, mainly due to lack of regulatory testing from the powers that be and quality control within companies, which is apparently common in the cannabis industry. Your best bet to avoid buying bogus products is to purchase your goods in states where cannabis is legal—because certain systems, standards, and protocols have already been put in place (such as seed-to-sale tracking).
The isolation of CBD was recorded back on 1940 by two independent investigation groups. The group of Adams and colleges successfully isolated it from cannabis 1. At the same time Jacob and Todd successfully isolated the cannabidiol from indian hemp resin 2. But was not until 1963 that Mechoulam and Shyo discovered the chemical structure of the CBD and enlightening the comprehension of the nature of the cannabinoids 3. At the next year 1964 Gaoni and Mechoulam finally elucidated the chemical structure of the main psychoactive compound of cannabis the THC matching the starting point of the modern pharmacology of cannabis 4.
Those warning letters aside, there’s not a lot of federal oversight right now over the claims being made or the products that are being sold. Cohen warned against buying CBD products online, because “there’s a lot of scams out there.” Yet his clinic sells CBD, and he admits, “I say ‘Don’t buy online,’ but ours is worth doing, because we know what we’re doing. We ship all over.”
That being said, it was unlikely that the federal government was interested in pursuing individuals complying with state-mandated regulations surrounding legalized cannabis for recreational use, although the CSA law still gives them authority to do so. However, the new Trump administration may change this thinking and users of legal marijuana and legal dispensaries await further action and clarifying rules.
I find it hilarious that there are trolls, even on product review pages. Anywho, I tried a bottle of their oil as a customer and not as an affiliate. I was suffering with a pretty rare condition and also had a severe iron deficiency. Both conditions resolved (I had had iron infusions months earlier that was taking its sweet time to make a difference with my symptoms), maybe a couple of months later. I also stoopped getting respiratory infections. I was able to get a lot more rest than I had been getting- eventually, the symptoms of my other conditions started disappearing. I have minimal symptoms now and I am working on keeping my diet nutrient-rich. I feel much better than I did before I started the oil. I haven’t used it again for financial reasons (I’m a sad cheapskate) but if I came into some money, I might buy another bottle.